Evotec Achieves BI Discovery Milestone

This is the fifth milestone achieved against an oncology target within Evotec's collaboration with Boehringer Ingelheim.

Drug development company Evotec has achieved a milestone in its research alliance with Boehringer Ingelheim, triggering a payment of $3.3 million. This was the fourth milestone achieved in 2011 and represents a total of $14.5 million of milestones achieved within that year.

The latest milestone was achieved for the identification and selection of a compound to be advanced into extended profiling prior to pre-clinical development within an oncology programme.